EVM
LGND icon

Eaton Vance Management’s Ligand Pharmaceuticals LGND Stock Holding History

Eaton Vance Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$431K Sell
8,015
-40
-0.5% -$2.35K ﹤0.01% 1367
2022
Q2 		$448K Sell
8,055
-1,060
-12% -$60.2K ﹤0.01% 1392
2022
Q1 		$639K Sell
9,115
-556
-6% -$40.3K ﹤0.01% 1467
2021
Q4 		$932K Buy
9,671
+96
+1% +$8.87K ﹤0.01% 1192
2021
Q3 		$697K Buy
9,575
+734
+8% +$56.8K ﹤0.01% 1162
2021
Q2 		$724K Buy
8,841
+746
+9% +$62.1K ﹤0.01% 1260
2021
Q1 		$770K Sell
8,095
-536,390
-99% -$50.7M ﹤0.01% 1184
2020
Q4 		$33.8M Buy
544,485
+161,439
+42% +$9.2M 0.05% 323
2020
Q3 		$22.8M Buy
383,046
+39,292
+11% +$2.68M 0.04% 339
2020
Q2 		$24M Buy
343,754
+48,257
+16% +$3.06M 0.05% 307
2020
Q1 		$13.4M Buy
295,497
+22,150
+8% +$1.26M 0.03% 355
2019
Q4 		$17.8M Buy
273,347
+58,970
+28% +$3.94M 0.03% 352
2019
Q3 		$13.3M Buy
214,377
+24,731
+13% +$1.55M 0.03% 388
2019
Q2 		$13.5M Buy
189,646
+76,325
+67% +$5.62M 0.03% 374
2019
Q1 		$8.89M Sell
113,321
-784
-0.7% -$59.4K 0.02% 440
2018
Q4 		$9.66M Buy
114,105
+15,397
+16% +$1.64M 0.03% 373
2018
Q3 		$16.9M Sell
98,708
-23,744
-19% -$3.58M 0.04% 305
2018
Q2 		$15.8M Sell
122,452
-224,331
-65% -$25M 0.04% 312
2018
Q1 		$35.7M Buy
346,783
+122,292
+54% +$12.1M 0.04% 293
2017
Q4 		$19.2M Sell
224,491
-70,352
-24% -$6.1M 0.05% 282
2017
Q3 		$25M Sell
294,843
-23,250
-7% -$1.84M 0.06% 238
2017
Q2 		$24.1M Sell
318,093
-361
-0.1% -$25.3K 0.06% 236
2017
Q1 		$21M Buy
318,454
+171,162
+116% +$11.3M 0.06% 244
2016
Q4 		$9.34M Buy
147,292
+112,852
+328% +$7.12M 0.03% 321
2016
Q3 		$2.19M Buy
+34,440
New +$2.53M 0.01% 569

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Eaton Vance Management's LGND Position: Q3 2022 in Review

Eaton Vance Management reduced its Ligand Pharmaceuticals (LGND) stake by 0.5% in Q3 2022, selling an estimated $2.35K and leaving 8,015 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Eaton Vance Management first reported a position in LGND in Q3 2016 and has held it in 25 quarters since. The position peaked at $35.7M in Q1 2018. 205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

  • Eaton Vance Management held 8,015 shares of Ligand Pharmaceuticals worth $431K as of Q3 2022.
  • Eaton Vance Management sold 40 Ligand Pharmaceuticals shares in Q3 2022, an estimated $2.35K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1367 holding.
  • Eaton Vance Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 25 quarters since.
  • Eaton Vance Management's Ligand Pharmaceuticals position peaked at $35.7M in Q1 2018.
  • 205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.